Urokinase plasminogen activator receptor (CD87): Something old, something new

Laboratory Hematology

Volumn 9, Issue 2, 2003, Pages 67-71

  Ge, Yimin ^a   Elghetany, M Tarek ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

CD87; Granulocytes; Urokinase plasminogen activator receptor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOTOXIC AGENT; DIPHTHERIA TOXIN; INTEGRIN; INTERLEUKIN 8; L SELECTIN; LIGAND; MESSENGER RNA; PEPTIDE DERIVATIVE; PLASMINOGEN; PSEUDOMONAS EXOTOXIN; RNA BINDING PROTEIN; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; CANCER INVASION; CANCER THERAPY; CELL ADHESION; CELL MOTILITY; CELL SURFACE; DATA ANALYSIS; DRUG TARGETING; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METASTASIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TISSUE DISTRIBUTION; TUMOR CELL;

CELL MOVEMENT; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 0344825232     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Vassalli DJD, Baccino D, Bellin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985;100:86-92.
2. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator: identification in human tumor cell lines and partial purification. J Biol Chem. 1988;263:2358-2363.
3. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15:398-408.
4. Colman RW, Pixley RA, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest. 1997;100:1481-1487.
5. Ploug M, Behrendt N, Lober D, Dano K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Haemost. 1991;17:183-193.
6. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS. 1999;107:160-167.
7. Ghannadan M, Baghestanian M, Wimazal F, et al. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J Invest Dermatol. 1998;11:689-695.
8. Ebner S, Lenz A, Reider D, Fritsch P, Schuler G, Romani N. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiology. 1998;198: 568-587.
9. Guilbert M, Ferland C, Bossé M, Flammand N, Lavigne S, Laviolette M. 5-Oxo-6,8,11,14-eicosatetraenoic acid induces important eosinophil transmigration through basement membrane components: comparison of normal and asthmatic eosinophils. Am J Respir Cell Mol Biol. 1999;21:97-104.
10. Plesner T, Ralfkiaer E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 1994;102:835-841.
11. Elghetany MT. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis. 2002; 28:260-274.
12. Elghetany MT, Patel J, Martinez J, Schwab H. CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis. Cytometry. 2003;51B:9-13.
13. Pedersen TL, Plesner T, Horn T, Hoyer-Hansen G, Sorensen S, Hansen NE. Subcellular distribution of urokinase and urokinase receptors in human neutrophils determined by immunoelectron microscopy. Ultrastructural Pathol. 2000;24:175-182.
14. Haddock RC, Spell ML, Baker CD 3rd, et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem. 1991;266:21466-21473.
15. Morita Y, Hayashi Y, Wang Y, et al. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology. 1997;25:856-861.
16. Bajpai A, Baker JB. Cryptic urokinase binding sites on human foreskin fibroblasts. Biochem Biophys Res Commun. 1985;133: 475-482.
17. Dumler I, Weis A, Mayboroda OA, et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem. 1998;273:315-321.
18. Zini JM, Murray SC, Graham CH, et al. Characterization of urokinase receptor expression by human placental trophoblasts. Blood. 1992;79:2917-2929.
19. Murphy G, Stanton H, Cowell S, et al. Mechanisms for prometrix metalloproteinase activation. APMIS. 1999;107:38-44.
20. Gyetko MR, Todd RF 3rd, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest. 1994;93:1380-1387.
21. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990;111:783-792.
22. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996;15:1572-1582.
23. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998;188:1029-1037.
24. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol. 2000;165:1513-1519.
25. Petty HR, Worth RG, Todd RF. Interaction of integrins with their partner proteins in leukocyte membranes. Immunol Res. 2002;25:75-95.
26. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem. 2002;383:2-19.
27. Sitrin RG, Pan PM, Blackwood RA, Huang J, Petty HR. Evidence for signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J Immunol. 2001;166:4822-4825.
28. Pedersen TL, Yong K, Pedersen JO, Hansen NE, Dano K, Plesner T. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal hemoglobinuria. Br J Haematol. 1996; 95:45-51.
29. Szekanecz Z, Haines GK, Koch AE. Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. J Clin Pathol. 1997;50:314-319.
30. Fauser S, Deininger MH, Kremsner PG, et al. Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria. J Neuroimmunol. 2000;111:234-240.
31. Walker DG, Lue LF, Beach TG. Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Res. 2002; 926:69-79.
32. Eugene-Olsen J, Gustafson P, Sidenius N, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis. 2002;6:686-692.
33. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic diseases: increased concentration in rheumatoid arthritis. Ann Rheum Dis. 1999;58:488-492.
34. Lanza F, Castoldi GL, Castagnari B, et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukemic cells. Br J Haematol. 1998;103:110-123.
35. Lopez-Pedrera C, Jardi M, del Mar Malagon M, et al. Tissue factor and urokinase plasminogen receptor and bleeding complications in leukemic patients. Thromb Haemost. 1997;77:62-70.
36. Hjertner O, Qvigstad G, Hjorth-Hansen H, et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol. 2000;109:815-822.
37. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis. Cancer. 1997;72:1-22.
38. Nakata S, Ito K, Fujimori M, et al. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer. 1998;79:179-186.
39. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases: a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat. 2000;61:1-12.
40. Champelovier P, Boucard N, Levacher G, Simon A, Seigneurin D, Praloran V. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res. 2002;30:301-309.
41. Memarzadeh S, Kozak KR, Chang L, et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci U S A. 2002;99:10647-10652.
42. Mohanam S, Gladson CL, Rao CN, Rao JS. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Front Biosci. 1999;4:D178-D187.
43. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636-643.
44. Guyton DP, Evans DM, Sloan-Stakleff KD. Urokinase plasminogen activator receptor (uPAR): a potential indicator of invasion for in situ breast cancer. Breast J. 2000;6:130-136.
45. Ohtani H, Pyke C, Dano K, Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer. 1995;62:691-696.
46. Pyke C, Graem N, Ralfkiaer E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993;53:1911-1915.
47. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol. 2000;190:430-436.
48. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000;60:2632-2635.
49. Kroon ME, Koolwijk P, van Goor H, et al. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol. 1999;154:1731-1742.
50. Graham CH, Forsdike J, Fitzgerald CJ, Macdonald-Goodfellow S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer. 1999; 80:617-623.
51. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa, N, Terao T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer. 1994;57:727-733.
52. Ploug M, Ostergaard S, Gardsvoll H, et al. Peptide-derived antagonists of the urokinase receptor: affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry. 2001; 40:12157-12168.
53. Sato S, Kopitz C, Schmalix WA, et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett. 2002; 528:212-216.
54. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J Biol Chem. 2000;275:10228-10234.
55. Mohan PM, Chintala SK, Mohanam S, et al. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res. 1999;59:3369-3373.
56. Li H, Lu H, Griscelli F, et al. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 1998;5:1105-1113.
57. Engelhard H, Narang C, Homer R, Duncan H. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun. 1996;227:400-405.
58. Shetty S, Idell S. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Arch Biochem Biophys. 1998; 356:265-279.
59. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha (2)-macroglobulin receptor. J Biol Chem. 2000;275: 7566-7573.
60. Frankel AE, Beran M, Hogge DE, et al. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Exp Hematol. 2002;30:1316-1323.
61. Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leukemia Res. 2003;27:79-84.